Related Experiment Video

Updated: Jan 4, 2026

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.5K

Protective Effects of Probiotic Consumption in Cardiovascular Disease in Systemic Lupus Erythematosus

Néstor de la Visitación1, Iñaki Robles-Vera1, Marta Toral2,3

  • 1Department of Pharmacology, School of Pharmacy, Universidad de Granada, 18071 Granada, Spain.

Nutrients
|November 8, 2019
PubMed

Insights

Probiotics may help manage systemic lupus erythematosus (SLE) by altering gut microbiota. While beneficial for SLE autoimmunity and nephritis, their preventive effects on renal and cardiovascular disease (CVD) in humans require further research.

Area of Science:

  • Immunology
  • Microbiology
  • Nephrology
  • Cardiology

Background:

  • Patients with systemic lupus erythematosus (SLE) exhibit higher rates of renal and cardiovascular disease (CVD) compared to the general population.
  • Emerging research highlights a causal link between gut microbiota and the immune system's response in SLE.
  • Altering gut microbiota through probiotic consumption shows potential in preventing SLE progression.

Purpose of the Study:

  • To review the role of gut microbiota in the pathogenesis of renal and cardiovascular disease in SLE.
  • To explore the potential of probiotics as a therapeutic strategy for SLE-related complications.

Main Methods:

  • Literature review synthesizing current evidence on gut microbiota, SLE, renal disease, and cardiovascular disease.
  • Analysis of studies investigating the impact of probiotics on SLE autoimmunity, nephritis, and CVD risk factors.

Main Results:

  • Probiotics demonstrate established benefits in managing SLE autoimmunity and nephritis.
  • Limited studies indicate potential protective effects of probiotics, specifically *Lactobacillus*, against CVD risk factors like endothelial dysfunction and hypertension in murine models.
  • Evidence for probiotic efficacy in preventing renal and CVD in human SLE patients remains inconclusive.

Conclusions:

  • Gut microbiota modulation via probiotics presents a promising avenue for managing SLE.
  • Further clinical trials are necessary to establish the preventive role of probiotics in renal and cardiovascular disease in human SLE patients.

Keywords:
endothelial dysfunctiongut microbiotahypertensionimmune responsenephritis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K
Prevention of Heat Stress Adverse Effects in Rats by Bacillus subtilis Strain07:57

Prevention of Heat Stress Adverse Effects in Rats by Bacillus subtilis Strain

Published on: July 11, 2016

7.9K

Related Concept Videos

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
352
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
286
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
554
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
793
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K